Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 445 to 455 of 455 entries
Sorted by: Best Match Show Resources per page
Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports.

The journal of obstetrics and gynaecology research

Nie LK, Zou HL, Cheng L, Zhang PH.
PMID: 34713941
J Obstet Gynaecol Res. 2022 Jan;48(1):262-265. doi: 10.1111/jog.15084. Epub 2021 Oct 29.

Adenomyosis is a common disease that affects many premenopausal women. Two patients with adenomyosis, aged 51 and 42 years, presented with dysmenorrhea and increased menstrual volume. They refused laparoscopy or laparotomy surgery and were not eligible for the levonorgestrel-releasing...

Cite
Nie LK, Zou HL, Cheng L, et al. Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports. J Obstet Gynaecol Res. 2021;48(1):262-265doi: 10.1111/jog.15084.
Nie, L. K., Zou, H. L., Cheng, L., & Zhang, P. H. (2022). Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports. The journal of obstetrics and gynaecology research, 48(1), 262-265. https://doi.org/10.1111/jog.15084
Nie, Le-Kai, et al. "Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports." The journal of obstetrics and gynaecology research vol. 48,1 (2022): 262-265. doi: https://doi.org/10.1111/jog.15084
Nie LK, Zou HL, Cheng L, Zhang PH. Subcutaneous etonogestrel implant combined with endometrial ablation for the treatment of adenomyosis: two case reports. J Obstet Gynaecol Res. 2022 Jan;48(1):262-265. doi: 10.1111/jog.15084. Epub 2021 Oct 29. PMID: 34713941.
Copy Download .nbib Format: NLM
Models and methods to characterise levonorgestrel release from intradermally administered contraceptives.

Drug delivery and translational research

Al Dalaty A, Gualeni B, Coulman SA, Birchall JC.
PMID: 34862590
Drug Deliv Transl Res. 2021 Dec 03; doi: 10.1007/s13346-021-01091-5. Epub 2021 Dec 03.

Microneedle (MN)-based technologies have been proposed as a means to facilitate minimally invasive sustained delivery of long-acting hormonal contraceptives into the skin. Intradermal administration is a new route of delivery for these contraceptives and therefore no established laboratory methods...

Cite
Al Dalaty A, Gualeni B, Coulman SA, et al. Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug Deliv Transl Res. 2021;doi: 10.1007/s13346-021-01091-5.
Al Dalaty, A., Gualeni, B., Coulman, S. A., & Birchall, J. C. (2021). Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug delivery and translational research, . https://doi.org/10.1007/s13346-021-01091-5
Al Dalaty, Adnan, et al. "Models and methods to characterise levonorgestrel release from intradermally administered contraceptives." Drug delivery and translational research vol. (2021). doi: https://doi.org/10.1007/s13346-021-01091-5
Al Dalaty A, Gualeni B, Coulman SA, Birchall JC. Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug Deliv Transl Res. 2021 Dec 03; doi: 10.1007/s13346-021-01091-5. Epub 2021 Dec 03. PMID: 34862590.
Copy Download .nbib Format: NLM
Ectopic Pregnancy in a Levonogestrel-Releasing Intrauterine Device User: A Case Report.

Cureus

Resta C, Dooley WM, Malligiannis Ntalianis K, Burugapalli S, Hussain M.
PMID: 34804718
Cureus. 2021 Oct 18;13(10):e18867. doi: 10.7759/cureus.18867. eCollection 2021 Oct.

Levonorgestrel-releasing intrauterine devices are considered to be a reliable contraceptive option with a low failure rate. The risk of ectopic pregnancy, however, if an unintended pregnancy occurs is significantly higher. In this study, we present a case of a...

Cite
Resta C, Dooley WM, Malligiannis Ntalianis K, et al. Ectopic Pregnancy in a Levonogestrel-Releasing Intrauterine Device User: A Case Report. Cureus. 2021;13(10):e18867doi: 10.7759/cureus.18867.
Resta, C., Dooley, W. M., Malligiannis Ntalianis, K., Burugapalli, S., & Hussain, M. (2021). Ectopic Pregnancy in a Levonogestrel-Releasing Intrauterine Device User: A Case Report. Cureus, 13(10), e18867. https://doi.org/10.7759/cureus.18867
Resta, Christina, et al. "Ectopic Pregnancy in a Levonogestrel-Releasing Intrauterine Device User: A Case Report." Cureus vol. 13,10 (2021): e18867. doi: https://doi.org/10.7759/cureus.18867
Resta C, Dooley WM, Malligiannis Ntalianis K, Burugapalli S, Hussain M. Ectopic Pregnancy in a Levonogestrel-Releasing Intrauterine Device User: A Case Report. Cureus. 2021 Oct 18;13(10):e18867. doi: 10.7759/cureus.18867. eCollection 2021 Oct. PMID: 34804718; PMCID: PMC8598246.
Copy Download .nbib Format: NLM
Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics

Laporte M, Charles CM, Metelus S, Peloggia A, de O Paez G, Juliato CT, Bahamondes L.
PMID: 34862968
Int J Gynaecol Obstet. 2021 Dec 04; doi: 10.1002/ijgo.14062. Epub 2021 Dec 04.

OBJECTIVES: To assess the reasons provided by women for choosing the use of the 52mg levonorgestrel intrauterine system (LNG-IUS) as a contraceptive method.MATERIALS AND METHODS: We conducted a cross sectional study from January 2021 to August 2021 at the...

Cite
Laporte M, Charles CM, Metelus S, et al. Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method. Int J Gynaecol Obstet. 2021;doi: 10.1002/ijgo.14062.
Laporte, M., Charles, C. M., Metelus, S., Peloggia, A., de O Paez, G., Juliato, C. T., & Bahamondes, L. (2021). Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, . https://doi.org/10.1002/ijgo.14062
Laporte, Montas, et al. "Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method." International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics vol. (2021). doi: https://doi.org/10.1002/ijgo.14062
Laporte M, Charles CM, Metelus S, Peloggia A, de O Paez G, Juliato CT, Bahamondes L. Reasons reported by women for choosing the levonorgestrel intrauterine system as a contraceptive method. Int J Gynaecol Obstet. 2021 Dec 04; doi: 10.1002/ijgo.14062. Epub 2021 Dec 04. PMID: 34862968.
Copy Download .nbib Format: NLM
Clinical efficacy of levonorgestrel intrauterine system (Mirena) combined with hysteroscopy in the treatment of perimenopausal AUB patients.

Pakistan journal of pharmaceutical sciences

Sun Y, Qian M, Hu D.
PMID: 34862877
Pak J Pharm Sci. 2021 Sep;34(5):2079-2083.

Perimenopausal abnormal uterine bleeding (AUB) is most common in ovulation dysfunction, which seriously compromises patients' health. This study aims to evaluate the efficacy of levonorgestrel intrauterine system (Mirena) plus hysteroscopy respectively in perimenopausal AUB. Sixty perimenopausal AUB patients treated...

Cite
Sun Y, Qian M, Hu D. Clinical efficacy of levonorgestrel intrauterine system (Mirena) combined with hysteroscopy in the treatment of perimenopausal AUB patients. Pak J Pharm Sci. 2021;34(5):2079-2083
Sun, Y., Qian, M., & Hu, D. (2021). Clinical efficacy of levonorgestrel intrauterine system (Mirena) combined with hysteroscopy in the treatment of perimenopausal AUB patients. Pakistan journal of pharmaceutical sciences, 34(5), 2079-2083.
Sun, Yujie, et al. "Clinical efficacy of levonorgestrel intrauterine system (Mirena) combined with hysteroscopy in the treatment of perimenopausal AUB patients." Pakistan journal of pharmaceutical sciences vol. 34,5 (2021): 2079-2083.
Sun Y, Qian M, Hu D. Clinical efficacy of levonorgestrel intrauterine system (Mirena) combined with hysteroscopy in the treatment of perimenopausal AUB patients. Pak J Pharm Sci. 2021 Sep;34(5):2079-2083. PMID: 34862877.
Copy Download .nbib Format: NLM
Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats.

Pathophysiology : the official journal of the International Society for Pathophysiology

Olatunji LA, Michael OS, Adewumi FO, Aiyegboyin IJ, Olatunji VA.
PMID: 21943687
Pathophysiology. 2012 Feb;19(1):29-34. doi: 10.1016/j.pathophys.2011.09.001. Epub 2011 Sep 22.

Women are exposed to sex steroids in several formulations such as oral contraceptives (OCs) and hormone replacement therapies. Estrogen is believed to have cardiometabolic protection effect; but its beneficial effects have recently been queried. The aim of the present...

Cite
Olatunji LA, Michael OS, Adewumi FO, et al. Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats. Pathophysiology. 2011;19(1):29-34doi: 10.1016/j.pathophys.2011.09.001.
Olatunji, L. A., Michael, O. S., Adewumi, F. O., Aiyegboyin, I. J., & Olatunji, V. A. (2012). Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats. Pathophysiology : the official journal of the International Society for Pathophysiology, 19(1), 29-34. https://doi.org/10.1016/j.pathophys.2011.09.001
Olatunji, L A, et al. "Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 19,1 (2012): 29-34. doi: https://doi.org/10.1016/j.pathophys.2011.09.001
Olatunji LA, Michael OS, Adewumi FO, Aiyegboyin IJ, Olatunji VA. Combined estrogen-progestogen but not progestogen-only oral contraceptive alters glucose tolerance and plasma lipid profile in female rats. Pathophysiology. 2012 Feb;19(1):29-34. doi: 10.1016/j.pathophys.2011.09.001. Epub 2011 Sep 22. PMID: 21943687.
Copy Download .nbib Format: NLM
Impact of polymer crosslinking on release mechanisms from long-acting levonorgestrel intrauterine systems.

International journal of pharmaceutics

Fanse S, Bao Q, Zou Y, Wang Y, Burgess DJ.
PMID: 34919997
Int J Pharm. 2022 Jan 25;612:121383. doi: 10.1016/j.ijpharm.2021.121383. Epub 2021 Dec 14.

Polydimethylsiloxane (PDMS) crosslinking density is a critical material attribute of levonorgestrel intrauterine systems (LNG-IUSs) that affects drug release and may have a significant influence on product performance and safety. Accordingly, the objective of the present work was to investigate...

Cite
Fanse S, Bao Q, Zou Y, et al. Impact of polymer crosslinking on release mechanisms from long-acting levonorgestrel intrauterine systems. Int J Pharm. 2021;612:121383doi: 10.1016/j.ijpharm.2021.121383.
Fanse, S., Bao, Q., Zou, Y., Wang, Y., & Burgess, D. J. (2022). Impact of polymer crosslinking on release mechanisms from long-acting levonorgestrel intrauterine systems. International journal of pharmaceutics, 612121383. https://doi.org/10.1016/j.ijpharm.2021.121383
Fanse, Suraj, et al. "Impact of polymer crosslinking on release mechanisms from long-acting levonorgestrel intrauterine systems." International journal of pharmaceutics vol. 612 (2022): 121383. doi: https://doi.org/10.1016/j.ijpharm.2021.121383
Fanse S, Bao Q, Zou Y, Wang Y, Burgess DJ. Impact of polymer crosslinking on release mechanisms from long-acting levonorgestrel intrauterine systems. Int J Pharm. 2022 Jan 25;612:121383. doi: 10.1016/j.ijpharm.2021.121383. Epub 2021 Dec 14. PMID: 34919997.
Copy Download .nbib Format: NLM
Models and methods to characterise levonorgestrel release from intradermally administered contraceptives.

Drug delivery and translational research

Al Dalaty A, Gualeni B, Coulman SA, Birchall JC.
PMID: 34862590
Drug Deliv Transl Res. 2022 Feb;12(2):335-349. doi: 10.1007/s13346-021-01091-5. Epub 2021 Dec 03.

Microneedle (MN)-based technologies have been proposed as a means to facilitate minimally invasive sustained delivery of long-acting hormonal contraceptives into the skin. Intradermal administration is a new route of delivery for these contraceptives and therefore no established laboratory methods...

Cite
Al Dalaty A, Gualeni B, Coulman SA, et al. Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug Deliv Transl Res. 2021;12(2):335-349doi: 10.1007/s13346-021-01091-5.
Al Dalaty, A., Gualeni, B., Coulman, S. A., & Birchall, J. C. (2022). Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug delivery and translational research, 12(2), 335-349. https://doi.org/10.1007/s13346-021-01091-5
Al Dalaty, Adnan, et al. "Models and methods to characterise levonorgestrel release from intradermally administered contraceptives." Drug delivery and translational research vol. 12,2 (2022): 335-349. doi: https://doi.org/10.1007/s13346-021-01091-5
Al Dalaty A, Gualeni B, Coulman SA, Birchall JC. Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug Deliv Transl Res. 2022 Feb;12(2):335-349. doi: 10.1007/s13346-021-01091-5. Epub 2021 Dec 03. PMID: 34862590.
Copy Download .nbib Format: NLM
Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States.

Contraception

Kaplan S, Bertoia ML, Wang FT, Zhou L, Lass A, Evans A, Dhanda S, Roy D, Seeger JD.
PMID: 34599911
Contraception. 2022 Jan;105:26-32. doi: 10.1016/j.contraception.2021.09.013. Epub 2021 Sep 30.

OBJECTIVES: To compare the safety profile of Seasonique, a 91-day levonorgestrel-containing combined oral contraceptive (COCSTUDY DESIGN: A new user cohort study was conducted in a US health care database from 2006 to 2017. Each 91-day COCRESULTS: Of the 25,593...

Cite
Kaplan S, Bertoia ML, Wang FT, et al. Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States. Contraception. 2021;105:26-32doi: 10.1016/j.contraception.2021.09.013.
Kaplan, S., Bertoia, M. L., Wang, F. T., Zhou, L., Lass, A., Evans, A., Dhanda, S., Roy, D., & Seeger, J. D. (2022). Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States. Contraception, 10526-32. https://doi.org/10.1016/j.contraception.2021.09.013
Kaplan, Sigal, et al. "Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States." Contraception vol. 105 (2022): 26-32. doi: https://doi.org/10.1016/j.contraception.2021.09.013
Kaplan S, Bertoia ML, Wang FT, Zhou L, Lass A, Evans A, Dhanda S, Roy D, Seeger JD. Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States. Contraception. 2022 Jan;105:26-32. doi: 10.1016/j.contraception.2021.09.013. Epub 2021 Sep 30. PMID: 34599911.
Copy Download .nbib Format: NLM
Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation.

EClinicalMedicine

Bahamondes L.
PMID: 33912819
EClinicalMedicine. 2021 Apr 14;34:100857. doi: 10.1016/j.eclinm.2021.100857. eCollection 2021 Apr.

No abstract available.

Cite
Bahamondes L. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation. EClinicalMedicine. 2021;34:100857doi: 10.1016/j.eclinm.2021.100857.
Bahamondes, L. (2021). Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation. EClinicalMedicine, 34100857. https://doi.org/10.1016/j.eclinm.2021.100857
Bahamondes, Luis. "Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation." EClinicalMedicine vol. 34 (2021): 100857. doi: https://doi.org/10.1016/j.eclinm.2021.100857
Bahamondes L. Weight change among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception did not influence early discontinuation. EClinicalMedicine. 2021 Apr 14;34:100857. doi: 10.1016/j.eclinm.2021.100857. eCollection 2021 Apr. PMID: 33912819; PMCID: PMC8066404.
Copy Download .nbib Format: NLM
Use of the Levonorgestrel Intrauterine System to Treat Heavy Menstrual Bleeding in Adolescents and Young Adults with Inherited Bleeding Disorders and Ehlers-Danlos Syndrome.

Journal of pediatric and adolescent gynecology

Huguelet PS, Laurin JL, Thornhill D, Moyer G.
PMID: 34775059
J Pediatr Adolesc Gynecol. 2021 Nov 11; doi: 10.1016/j.jpag.2021.11.002. Epub 2021 Nov 11.

STUDY OBJECTIVE: To report on the rate of amenorrhea among adolescents and young adults with a bleeding diathesis after insertion of the 52-mg levonorgestrel intrauterine system (LNG-IUS) DESIGN: Retrospective chart review SETTING: Tertiary care, multidisciplinary Gynecology-Hematology clinic or Adolescent...

Cite
Huguelet PS, Laurin JL, Thornhill D, et al. Use of the Levonorgestrel Intrauterine System to Treat Heavy Menstrual Bleeding in Adolescents and Young Adults with Inherited Bleeding Disorders and Ehlers-Danlos Syndrome. J Pediatr Adolesc Gynecol. 2021;doi: 10.1016/j.jpag.2021.11.002.
Huguelet, P. S., Laurin, J. L., Thornhill, D., & Moyer, G. (2021). Use of the Levonorgestrel Intrauterine System to Treat Heavy Menstrual Bleeding in Adolescents and Young Adults with Inherited Bleeding Disorders and Ehlers-Danlos Syndrome. Journal of pediatric and adolescent gynecology, . https://doi.org/10.1016/j.jpag.2021.11.002
Huguelet, Patricia S, et al. "Use of the Levonorgestrel Intrauterine System to Treat Heavy Menstrual Bleeding in Adolescents and Young Adults with Inherited Bleeding Disorders and Ehlers-Danlos Syndrome." Journal of pediatric and adolescent gynecology vol. (2021). doi: https://doi.org/10.1016/j.jpag.2021.11.002
Huguelet PS, Laurin JL, Thornhill D, Moyer G. Use of the Levonorgestrel Intrauterine System to Treat Heavy Menstrual Bleeding in Adolescents and Young Adults with Inherited Bleeding Disorders and Ehlers-Danlos Syndrome. J Pediatr Adolesc Gynecol. 2021 Nov 11; doi: 10.1016/j.jpag.2021.11.002. Epub 2021 Nov 11. PMID: 34775059.
Copy Download .nbib Format: NLM
Showing 445 to 455 of 455 entries